Evolus, Inc. EOLS
Institutional shares held
47.8 Million
130K
calls
51K
puts
Total value of holdings
$573M
$1.56M
calls
$611K
puts
Market Cap
$695M
56,094,800
Shares Out.
Institutional ownership
85.2%
# of Institutions
169
We take great care to ensure that the data presented and summarized in this overview for Evolus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EOLS
View all-
Perceptive Advisors LLC New York, NY5.36MShares$66.4 Million2.27% of portfolio
-
Tang Capital Management LLC San Diego, CA4.85MShares$60.1 Million6.69% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$49.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.2MShares$39.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$35 Million2.72% of portfolio
-
Stonepine Capital Management, LLC Bend, OR1.37MShares$17 Million14.02% of portfolio
-
State Street Corp Boston, MA1.28MShares$15.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.21MShares$15 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT1.17MShares$14.5 Million8.76% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.04MShares$12.9 Million1.43% of portfolio
Latest Institutional Activity in EOLS
Top Purchases
Top Sells
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Transactions at EOLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 06
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,276
-2.16%
|
$45,864
$14.98 P/Share
|
|
Aug 30
2024
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
5,631
-6.4%
|
$84,465
$15.85 P/Share
|
|
Jul 01
2024
|
Albert G White Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,014
+50.0%
|
-
|
|
Jun 06
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
175,940
-24.81%
|
$2,111,280
$12.59 P/Share
|
|
Jun 06
2024
|
David Moatazedi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
175,940
+19.88%
|
$1,231,580
$7.28 P/Share
|
|
Jun 05
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
155,278
-22.55%
|
$1,863,336
$12.92 P/Share
|
|
Jun 05
2024
|
David Moatazedi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
155,278
+18.4%
|
$776,390
$5.46 P/Share
|
|
Jun 04
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
140,214
-20.82%
|
$1,682,568
$12.73 P/Share
|
|
Jun 03
2024
|
Vikram Malik Director |
SELL
Open market or private sale
|
Direct |
7,500
-2.95%
|
$90,000
$12.96 P/Share
|
|
May 14
2024
|
David N Gill Director |
SELL
Open market or private sale
|
Direct |
6,718
-16.51%
|
$80,616
$12.6 P/Share
|
|
May 13
2024
|
Vikram Malik Director |
SELL
Open market or private sale
|
Direct |
28,000
-9.93%
|
$336,000
$12.93 P/Share
|
|
May 13
2024
|
David N Gill Director |
SELL
Open market or private sale
|
Direct |
3,643
-8.22%
|
$43,716
$12.72 P/Share
|
|
May 10
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,423
-1.57%
|
$29,076
$12.72 P/Share
|
|
May 10
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
3,441
-0.92%
|
$41,292
$12.72 P/Share
|
|
May 10
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
16,051
-2.33%
|
$192,612
$12.72 P/Share
|
|
Mar 27
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,236
-0.9%
|
$81,068
$13.86 P/Share
|
|
Mar 19
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
96,566
-12.19%
|
$1,255,358
$13.92 P/Share
|
|
Mar 19
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,672
-3.55%
|
$73,736
$13.92 P/Share
|
|
Mar 19
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
27,603
-6.9%
|
$358,839
$13.92 P/Share
|
|
Feb 22
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,821
-1.13%
|
$23,673
$13.08 P/Share
|
Last 12 Months Summary
Buy / Acquisition
710K
Shares
From
12
Insiders
| Grant, award, or other acquisition | 379K shares |
|---|---|
| Exercise of conversion of derivative security | 331K shares |
Sell / Disposition
790K
Shares
From
7
Insiders
| Open market or private sale | 790K shares |
|---|